See the DrugPatentWatch profile for Qulipta
Qulipta, also known by its generic name atogepant, is an oral medication prescribed for the preventive treatment of episodic migraine [1][2]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, a class of drugs designed to block the action of CGRP, a molecule implicated in migraine pain [3].
What is Qulipta used for?
Qulipta is indicated for adults with a history of episodic migraine who have had 4 or more migraine days per month during the previous 3 months [1]. It is taken as a once-daily tablet [1].
How does Qulipta work?
Qulipta functions by blocking the activity of CGRP. CGRP is a neuropeptide that plays a significant role in the pathophysiology of migraine, including pain transmission and vasodilation [3]. By inhibiting CGRP receptor binding, Qulipta aims to reduce the frequency of migraine attacks [3].
When does Qulipta patent protection expire?
Patent information for Qulipta can be complex and subject to change. DrugPatentWatch.com is a resource that tracks pharmaceutical patent expirations and exclusivity periods [4]. General patent information for atogepant can be found on platforms like DrugPatentWatch.com, which may provide details on anticipated patent expiry dates and exclusivity terms that could affect generic availability [4].
What are the potential side effects of Qulipta?
Common side effects associated with Qulipta include upper respiratory tract infection, nausea, and fatigue [1]. Patients should consult with their healthcare provider for a comprehensive list of potential side effects and to discuss any concerns [1].
How does Qulipta compare to other migraine prevention medications?
Qulipta belongs to the oral CGRP antagonist class, distinct from injectable CGRP monoclonal antibodies and other classes of preventive migraine medications [3]. Its oral formulation offers a different administration route compared to injectable treatments. Comparisons with specific medications like Aimovig, Ajovy, or Emgality, or other oral options, would involve assessing efficacy, side effect profiles, dosing, and cost, as well as patient-specific responses [3].
Can generic versions of Qulipta be available?
The availability of generic versions of Qulipta depends on the expiration of its patents and any associated market exclusivities [4]. Generic drug entry typically occurs after these protections have ended, potentially leading to lower medication costs. Information regarding patent status and potential generic launches can be found on specialized databases [4].
What clinical data supports Qulipta's use?
Clinical trials have demonstrated Qulipta's efficacy in reducing monthly migraine days in adults with episodic migraine [2]. These studies typically assess the drug's performance against a placebo and evaluate various endpoints related to migraine frequency and severity [2].
What are patient considerations for taking Qulipta?
Patients considering Qulipta should discuss their medical history, including any liver problems, with their doctor, as the drug has a boxed warning regarding potential liver injury [1]. It is crucial to inform the healthcare provider about all other medications being taken to avoid potential drug interactions [1].
---
1. Qulipta [package insert]. Morristown, NJ: AbbVie Inc.; 2021.
2. Edvinsson L. CGRP receptor antagonists in migraine treatment. Br J Clin Pharmacol. 2021;87(9):3343-3351. doi:10.1111/bcp.14732
3. DrugPatentWatch.com. (n.d.). Atogepant. Retrieved from https://drugpatentwatch.com/
4. DrugPatentWatch.com. (n.d.). Pharmaceutical Patent Expirations & Drug Longevity. Retrieved from https://drugpatentwatch.com/